FindTrial
Sign In

TAWIS - Evaluation of TNF-alpha antagonists (Infliximab) withdrawal in sarcoidosis : a prospective, randomized, controlled trial.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-516965-35-00
Enrollment
90
Registered
2024-10-28
Start date
2024-10-28
Completion date
Unknown
Last updated
2025-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune system disorders

Brief summary

The primary endpoint is the percentage of patients with major relapses in the 2 groups

Interventions

DRUGMETHOTREXATE
DRUGINFLIXIMAB
DRUGAZATHIOPRINE

Sponsors

Assistance Publique Hopitaux De Paris
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the percentage of patients with major relapses in the 2 groups—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026